A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): Phase 1 results

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 8051-8051 ◽  
Author(s):  
V. Papadimitrakopoulou ◽  
G. R. Blumenschein ◽  
N. B. Leighl ◽  
J. Bennouna ◽  
J. C. Soria ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Phase 1 ◽  
Small Cell ◽  
Small Cell Lung ◽  
Line Therapy ◽  
Previously Treated

scholarly journals Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study

Lung Cancer ◽  
2018 ◽  
Vol 125 ◽  
pp. 273-281 ◽  
Author(s):  
Shirish M. Gadgeel ◽  
James P. Stevenson ◽  
Corey J. Langer ◽  
Leena Gandhi ◽  
Hossein Borghaei ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Phase 1 ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Platinum Based Chemotherapy

Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 8011-8011 ◽  
Author(s):  
Amita Patnaik ◽  
Mark A. Socinski ◽  
Matthew A. Gubens ◽  
Leena Gandhi ◽  
James Stevenson ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Phase 1 ◽  
Small Cell ◽  
Second Line ◽  
Small Cell Lung ◽  
Second Line Therapy ◽  
Phase 1 Study ◽  
Line Therapy

scholarly journals Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

2017 ◽  
Vol 28 (4) ◽  
pp. 874-881 ◽  
Author(s):  
R. Hui ◽  
E.B. Garon ◽  
J.W. Goldman ◽  
N.B. Leighl ◽  
M.D. Hellmann ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Phase 1 ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Phase 1 Trial ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non–Small-Cell Lung Cancer

2015 ◽  
Vol 10 (2) ◽  
pp. 346-352 ◽  
Author(s):  
Isamu Okamoto ◽  
Masaki Miyazaki ◽  
Masayuki Takeda ◽  
Masaaki Terashima ◽  
Koichi Azuma ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Phase 1 ◽  
Japanese Patients ◽  
Small Cell ◽  
Small Cell Lung ◽  
Phase 1 Study ◽  
Previously Treated ◽  
Bibf 1120

scholarly journals Phase 1-2a Multicenter Dose-Ranging Study of Canfosfamide in Combination with Carboplatin and Paclitaxel as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer

2009 ◽  
Vol 4 (11) ◽  
pp. 1389-1396 ◽  
Author(s):  
Lecia V. Sequist ◽  
Panos M. Fidias ◽  
Jennifer S. Temel ◽  
Tatjana Kolevska ◽  
Michael S. Rabin ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Phase 1 ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Dose Ranging
Sign in / Sign up

Export Citation Format

Share Document